GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hamlet BioPharma AB publ (STU:7ZT) » Definitions » EV-to-EBIT

Hamlet BioPharma AB publ (STU:7ZT) EV-to-EBIT : -15.28 (As of May. 28, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Hamlet BioPharma AB publ EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hamlet BioPharma AB publ's Enterprise Value is €65.42 Mil. Hamlet BioPharma AB publ's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-4.28 Mil. Therefore, Hamlet BioPharma AB publ's EV-to-EBIT for today is -15.28.

The historical rank and industry rank for Hamlet BioPharma AB publ's EV-to-EBIT or its related term are showing as below:

STU:7ZT' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.61   Med: 0   Max: 0
Current: -14.61

STU:7ZT's EV-to-EBIT is ranked worse than
100% of 477 companies
in the Biotechnology industry
Industry Median: 8.27 vs STU:7ZT: -14.61

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Hamlet BioPharma AB publ's Enterprise Value for the quarter that ended in Dec. 2024 was €49.95 Mil. Hamlet BioPharma AB publ's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-4.28 Mil. Hamlet BioPharma AB publ's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -8.57%.


Hamlet BioPharma AB publ EV-to-EBIT Historical Data

The historical data trend for Hamlet BioPharma AB publ's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hamlet BioPharma AB publ EV-to-EBIT Chart

Hamlet BioPharma AB publ Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.94 -109.53 -22.86 -14.38 -15.79

Hamlet BioPharma AB publ Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.67 -7.60 -15.79 -15.54 -13.02

Competitive Comparison of Hamlet BioPharma AB publ's EV-to-EBIT

For the Biotechnology subindustry, Hamlet BioPharma AB publ's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hamlet BioPharma AB publ's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hamlet BioPharma AB publ's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hamlet BioPharma AB publ's EV-to-EBIT falls into.


;
;

Hamlet BioPharma AB publ EV-to-EBIT Calculation

Hamlet BioPharma AB publ's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=65.424/-4.282
=-15.28

Hamlet BioPharma AB publ's current Enterprise Value is €65.42 Mil.
Hamlet BioPharma AB publ's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hamlet BioPharma AB publ  (STU:7ZT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Hamlet BioPharma AB publ's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-4.282/49.95076
=-8.57 %

Hamlet BioPharma AB publ's Enterprise Value for the quarter that ended in Dec. 2024 was €49.95 Mil.
Hamlet BioPharma AB publ's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hamlet BioPharma AB publ EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Hamlet BioPharma AB publ's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hamlet BioPharma AB publ Business Description

Traded in Other Exchanges
Address
Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.

Hamlet BioPharma AB publ Headlines

No Headlines